CZ143998A3 - Substituované diaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití - Google Patents

Substituované diaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití Download PDF

Info

Publication number
CZ143998A3
CZ143998A3 CZ981439A CZ143998A CZ143998A3 CZ 143998 A3 CZ143998 A3 CZ 143998A3 CZ 981439 A CZ981439 A CZ 981439A CZ 143998 A CZ143998 A CZ 143998A CZ 143998 A3 CZ143998 A3 CZ 143998A3
Authority
CZ
Czechia
Prior art keywords
group
formula
substituted
alkyl
phenyl
Prior art date
Application number
CZ981439A
Other languages
Czech (cs)
English (en)
Inventor
Werner Dr. Thorwart
Wilfried Dr. Schwab
Manfred Dr. Schudok
Burkhard Dr. Haase
Bernhard Dr. Neises
Günter Dr. Billen
Original Assignee
Hoechst Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19719585A external-priority patent/DE19719585A1/de
Priority claimed from DE19719428A external-priority patent/DE19719428A1/de
Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft
Publication of CZ143998A3 publication Critical patent/CZ143998A3/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CZ981439A 1997-05-09 1998-05-07 Substituované diaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití CZ143998A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19719585A DE19719585A1 (de) 1997-05-09 1997-05-09 Substituierte Diaminocarbonsäuren
DE19719428A DE19719428A1 (de) 1997-05-12 1997-05-12 Substituierte Diaminocarbonsäuren

Publications (1)

Publication Number Publication Date
CZ143998A3 true CZ143998A3 (cs) 1998-11-11

Family

ID=26036417

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ981439A CZ143998A3 (cs) 1997-05-09 1998-05-07 Substituované diaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití

Country Status (18)

Country Link
US (2) US6159995A (enExample)
EP (1) EP0877019B1 (enExample)
JP (1) JP4177484B2 (enExample)
KR (1) KR19980086893A (enExample)
AR (1) AR012675A1 (enExample)
AT (1) ATE210639T1 (enExample)
AU (1) AU736700B2 (enExample)
BR (1) BR9801604A (enExample)
CA (1) CA2237052A1 (enExample)
CZ (1) CZ143998A3 (enExample)
DE (1) DE59802394D1 (enExample)
DK (1) DK0877019T3 (enExample)
ES (1) ES2165640T3 (enExample)
HU (1) HUP9801045A3 (enExample)
ID (1) ID20809A (enExample)
PL (1) PL326218A1 (enExample)
PT (1) PT877019E (enExample)
TR (1) TR199800818A3 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
CN1195735C (zh) * 1998-02-04 2005-04-06 诺瓦提斯公司 抑制使基质退化的金属蛋白酶的磺酰氨基衍生物
CN1304402A (zh) * 1998-04-03 2001-07-18 三共株式会社 磺酰胺衍生物
ATE227295T1 (de) 1998-07-16 2002-11-15 Aventis Pharma Gmbh Phosphin- und phosphonsäurederivate als arzneimittel
EP1165530A2 (en) 1999-03-03 2002-01-02 The Procter & Gamble Company Dihetero-substituted metalloprotease inhibitors
IL145089A0 (en) * 1999-03-03 2002-06-30 Procter & Gamble Alkenyl-and alkynyl-containing metalloprotease inhibitors
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
US6506786B2 (en) * 2001-02-13 2003-01-14 Pharmacor Inc. HIV protease inhibitors based on amino acid derivatives
US20040235896A1 (en) * 2001-03-14 2004-11-25 Fujimoto Roger Aki Certain azacycloalkyl substituted acetic acid derivatives
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
ES2539527T3 (es) * 2005-04-27 2015-07-01 Taimed Biologics, Inc. Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
JP2009517412A (ja) * 2005-11-30 2009-04-30 アンブリリア バイオファーマ インコーポレイテッド アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法
US8410300B2 (en) 2006-09-21 2013-04-02 Taimed Biologics, Inc. Protease inhibitors
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US8093265B2 (en) 2007-03-09 2012-01-10 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
CA2970578C (en) 2014-12-17 2024-01-02 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
EP3560917B1 (en) * 2016-12-22 2023-12-20 Guangzhou Chinaray Optoelectronic Materials Ltd. Polymer containing furan crosslinking group and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2764262B2 (ja) * 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
TW201303B (enExample) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US6022898A (en) * 1994-06-22 2000-02-08 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) * 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
US5977141A (en) * 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
WO1997045402A1 (fr) 1996-05-24 1997-12-04 Ono Pharmaceutical Co., Ltd. Derives de phenylsulfonamide

Also Published As

Publication number Publication date
AU6482498A (en) 1998-11-12
AU736700B2 (en) 2001-08-02
TR199800818A2 (xx) 1998-11-23
TR199800818A3 (tr) 1998-11-23
PT877019E (pt) 2002-05-31
ES2165640T3 (es) 2002-03-16
KR19980086893A (ko) 1998-12-05
HUP9801045A2 (hu) 1999-06-28
EP0877019B1 (de) 2001-12-12
DE59802394D1 (de) 2002-01-24
EP0877019A1 (de) 1998-11-11
ATE210639T1 (de) 2001-12-15
CA2237052A1 (en) 1998-11-09
PL326218A1 (en) 1998-11-23
AR012675A1 (es) 2000-11-08
BR9801604A (pt) 1999-06-08
JPH11228529A (ja) 1999-08-24
DK0877019T3 (da) 2002-04-08
HU9801045D0 (en) 1998-07-28
US6355673B1 (en) 2002-03-12
US6159995A (en) 2000-12-12
ID20809A (id) 1999-03-11
JP4177484B2 (ja) 2008-11-05
HUP9801045A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
CZ143998A3 (cs) Substituované diaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití
CZ143898A3 (cs) Sulfonylaminokarboxylové kyseliny, způsob jejich přípravy, léčivo, které je obsahuje, a jejich použití
CA2321538A1 (en) Disubstituted pyrazolines and triazolines as factor xa inhibitors
SK17252002A3 (sk) Deriváty acylfenylmočoviny, spôsoby ich výroby a použitie ako liečivo
CA2321348A1 (en) Aromatic derivatives with hiv integrase inhibitory properties
CA2250464A1 (en) Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
CZ300127B6 (cs) Zpusob prípravy meziproduktu inhibujících proteázy retroviru
ES2294103T3 (es) Inhibidores de vih proteasa con base en derivados de aminoacidos.
US5932550A (en) Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
IE60332B1 (en) N-(2'aminophenyl)-benzamide-derivatives, process for their preparation and their use in the control of neoplastic diseases
CN1658877B (zh) 碱性非肽缓激肽拮抗剂及其药物组合物
RU2632206C2 (ru) Новые алкилирующие средства
US6706753B2 (en) Integrin receptor inhibitors
ES2235383T3 (es) Beta-alaninas sustituidas.
KR20010080385A (ko) Ｎ-아릴설포닐 아미노산 오메가 아미드
KR101771760B1 (ko) 우레탄, 요소, 아미딘 및 관련된 Ｘａ 인자의 억제제
Borrello et al. Synthesis of carboxamide-containing tranylcypromine analogues as LSD1 (KDM1A) inhibitors targeting acute myeloid leukemia
EP1480941B1 (en) Urea derivatives as hiv aspartyl protease inhibitors
WO2016107227A1 (zh) 吡咯酰胺类化合物及其制备方法与用途
RU2196768C2 (ru) Замещенные диаминокарбоновые кислоты
EP1270569A1 (en) Substituted tryptophan derivatives
CA2374362C (en) Urea derivatives as hiv aspartyl protease inhibitors
US5310916A (en) Trifunctional agents useful as irreversible inhibitors of A1-adenosine receptors
CN105153163B (zh) 2,9‑二取代嘌呤‑6‑氨基异羟肟酸类组蛋白去乙酰化酶抑制剂及制备方法和应用
WO2016107541A1 (zh) 吡咯酰胺类化合物及其制备方法与用途

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic